BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 19743519)

  • 1. The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Wang Y; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Pediatr Blood Cancer; 2009 Dec; 53(6):1100-6. PubMed ID: 19743519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.
    Sartor MM; Garvin F; Antonenas V; Bradstock KF; Gottlieb DJ
    Bone Marrow Transplant; 2007 Nov; 40(9):851-7. PubMed ID: 17704793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.
    Keever-Taylor CA; Klein JP; Eastwood D; Bredeson C; Margolis DA; Burns WH; Vesole DH
    Bone Marrow Transplant; 2001 Apr; 27(8):791-800. PubMed ID: 11477435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia.
    Zhang C; Zhang X; Chen XH; Gao L; Gao L; Kong PY; Peng XG; Sun AH; Wang QY
    Transfus Apher Sci; 2011 Jun; 44(3):249-55. PubMed ID: 21550308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?
    Singhal S; Powles R; Treleaven J; Kulkarni S; Sirohi B; Horton C; Millar B; Shepherd V; Tait D; Saso R; Rowland A; Long S; Mehta J
    Bone Marrow Transplant; 2000 Sep; 26(5):489-96. PubMed ID: 11019837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.
    Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE
    Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
    Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
    Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.
    Chang YJ; Zhao XY; Huo MR; Xu LP; Liu DH; Liu KY; Huang XJ
    Am J Hematol; 2011 Feb; 86(2):227-30. PubMed ID: 21264916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
    Chang YJ; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
    Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
    Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics.
    Diaz MA; Alegre A; Villa M; Granda A; de la Vega A; Ramirez M; Ruano D; Gonzalez A; Merino JM; Madero L
    Bone Marrow Transplant; 1996 Oct; 18(4):699-703. PubMed ID: 8899183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency.
    Lanfranchi A; Verardi R; Tettoni K; Neva A; Mazzolari E; Pennacchio M; Pasic S; Ugazio AG; Albertini A; Porta F
    Haematologica; 2000 Nov; 85(11 Suppl):41-6. PubMed ID: 11268323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.